Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR52 | Q9Y2T5 | 11/20 | 0.49 |
| ▸ | HTR2B | P41595 | 1/20 | 0.49 |
| ▸ | CCR1 | P32246 | 5/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | BRAF | P15056 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14033903 | 0.87 | ALDH1A1 (0.49) | GPR52KDM4EMAPTALDH1A1 | |
| SCHEMBL14033045 | 0.83 | PDE2A (0.41) | GPR52KDM4EMAPTALDH1A1POLB | |
| SCHEMBL14033204 | 0.82 | KDM4E (0.45) | GPR52HTR2BCCR1KDM4EALDH1A1 | |
| SCHEMBL4439055 | 0.80 | BRAF (0.54) | KDM4EMAPTALDH1A1BRAF | |
| SCHEMBL4725426 | 0.76 | RUVBL1 (0.57) | NPSR1KDM4EMAPTALDH1A1 | |
| SCHEMBL14033657 | 0.75 | GPR52 (0.49) | GPR52KDM4EALDH1A1BRAF | |
| SCHEMBL4781535 | 0.74 | KDM4E (0.58) | GPR52NPSR1KDM4EMAPTALDH1A1 | |
| SCHEMBL4725875 | 0.73 | LMNA (0.56) | NPSR1KDM4EMAPTALDH1A1POLB | |
| SCHEMBL14033910 | 0.71 | RIPK1 (0.44) | NPSR1KDM4EMAPTALDH1A1POLB | |
| SCHEMBL14033041 | 0.71 | KDM5A (0.46) | GPR52KDM4EALDH1A1BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080255153-A1 | New compounds | BIOVITRUM AB (PUBL) (SE) | 2008-10-16 | — | — | US | disclosed |
| US-20080255153-A1 | New compounds | BIOVITRUM AB (PUBL) (SE) | 2008-10-16 | — | — | US | disclosed |
| WO-2008116898-A1 | PYRAZOLO [1,5-A]PYRIMIDINES AS INHIBITORS OF STEAROYL-COA DESATURASE | BIOVITRUM AB (PUBL) (SE) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255153-A1 | New compounds | SCD, SCD5, FADS2 | GPR52 1409/4885HTR2B 4619/4885CCR1 1615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.